A detailed history of Icici Prudential Asset Management CO LTD transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Icici Prudential Asset Management CO LTD holds 3,369 shares of VRTX stock, worth $1.52 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
3,369
Previous 2,834 18.88%
Holding current value
$1.52 Million
Previous $1.33 Million 17.92%
% of portfolio
0.17%
Previous 0.16%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$460.0 - $505.78 $246,100 - $270,592
535 Added 18.88%
3,369 $1.57 Million
Q2 2024

Jul 22, 2024

BUY
$392.81 - $485.53 $103,309 - $127,694
263 Added 10.23%
2,834 $1.33 Million
Q1 2024

May 08, 2024

BUY
$407.69 - $446.08 $28,538 - $31,225
70 Added 2.8%
2,571 $1.07 Million
Q4 2023

Jan 19, 2024

BUY
$343.0 - $410.68 $70,315 - $84,189
205 Added 8.93%
2,501 $1.02 Million
Q3 2023

Nov 02, 2023

BUY
$338.18 - $362.46 $184,308 - $197,540
545 Added 31.13%
2,296 $798,000
Q2 2023

Jul 20, 2023

BUY
$314.42 - $351.91 $33,014 - $36,950
105 Added 6.38%
1,751 $616,000
Q1 2023

May 04, 2023

BUY
$283.23 - $323.1 $101,113 - $115,346
357 Added 27.7%
1,646 $518,000
Q4 2022

Feb 07, 2023

BUY
$285.76 - $321.48 $99,444 - $111,875
348 Added 36.98%
1,289 $372,000
Q3 2022

Oct 28, 2022

BUY
$273.83 - $305.53 $49,015 - $54,689
179 Added 23.49%
941 $272,000
Q2 2022

Aug 05, 2022

BUY
$234.96 - $292.55 $7,283 - $9,069
31 Added 4.24%
762 $214,000
Q1 2022

May 09, 2022

BUY
$221.42 - $260.97 $23,027 - $27,140
104 Added 16.59%
731 $188,000
Q4 2021

Feb 08, 2022

BUY
$177.01 - $223.45 $110,985 - $140,103
627 New
627 $138,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Icici Prudential Asset Management CO LTD Portfolio

Follow Icici Prudential Asset Management CO LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Icici Prudential Asset Management CO LTD, based on Form 13F filings with the SEC.

News

Stay updated on Icici Prudential Asset Management CO LTD with notifications on news.